APLS250117P26000
- 0.00
- 0.000.00%
Apellis Pharmaceuticals Newsroom
Express News | Apellis Pharmaceuticals Inc - Board Expands to Seven Directors, Six Independent
Express News | Apellis Announces Keli Walbert to Join the Board of Directors
Press Release: Apellis Announces Keli Walbert to Join the Board of Directors
Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)
RBC Raises Price Target on Apellis Pharmaceuticals to $26 From $24, Keeps Sector Perform Rating
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS): When Will It Breakeven?
Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Apellis Pharmaceuticals Price Target Announced at $36.00/Share by Goldman Sachs
Goldman Sachs Downgrades Apellis Pharmaceuticals(APLS.US) to Hold Rating
Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) to a Hold
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $47
Buy Rating for Apellis Pharmaceuticals: Promising Growth Potential of Syfovre in Geographic Atrophy Market
Worst Performing Stocks for Tax Loss Selling – Wolfe
Express News | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Fly 27% But Investors Aren't Buying For Growth
RBC Capital Remains a Hold on Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences